Ghrelin, an endogenous ligand for the growth hormone secretagogue receptor, is synthesized principally in the stomach and is released in response to fasting. Ghrelin is structurally related to motilin and, together, they represent a novel family of gut–brain regulatory peptides. In addition to having a powerful effect on the secretion of growth hormone, ghrelin stimulates energy production and signals directly to the hypothalamic regulatory nuclei that control energy homeostasis. The study of ghrelin has extended our understanding of how growth is controlled, and has shown that the stomach is an important component of this system.
The identification of growth hormone secretagogues led to the discovery of a new receptor with homology to the motilin receptor. Subsequent studies led to the identification of its endogenous ligand — ghrelin. Ghrelin can indeed stimulate the release of growth hormone from the pituitary in a way that is independent of the action of growth-hormone-releasing hormone.
In addition to its effect on the release of growth hormone, ghrelin is an important regulator of food intake. It is released from the stomach in response to fasting, and increases feeding behaviour by acting on the arcuate nucleus of the hypothalamus.
The action of ghrelin is opposite to that of another important regulator of food intake — leptin. Leptin is released from adipose tissue, and its plasma levels decrease in response to fasting. This molecule also acts on the arcuate nucleus of the hypothalamus, where it has an anorexigenic effect.
The discovery of ghrelin has several clinical implications. It can be used to stimulate the release of growth hormone in cases of human deficiency, by acting on the endogenous oscillators that control pulsatile hormone release. It can also be used for the regulation of body weight by stimulating food intake, particularly in conditions accompanied by cachexia, such as cancer and AIDS.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
The association of appetite and hormones (leptin, ghrelin, and Insulin) with resting metabolic rate in overweight/ obese women: a case–control study
BMC Nutrition Open Access 29 April 2022
The gut hormone Allatostatin C/Somatostatin regulates food intake and metabolic homeostasis under nutrient stress
Nature Communications Open Access 04 February 2022
Scientific Reports Open Access 11 September 2018
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Elmquist, J. K., Maratos-Flier, E., Saper, C. B. & Flier, J. S. Unraveling the central nervous system pathways underlying responses to leptin. Nature Neurosci. 1, 445–450 (1998).
Flier, J. S. & Maratos-Flier, E. Obesity and the hypothalamus: novel peptides for new pathways. Cell 92, 437–440 (1998).
Woods, S. C., Seeley, R. J., Porte, D. Jr & Schwartz, M. W. Signals that regulate food intake and energy homeostasis. Science 280, 1378–1383 (1998).
Bray, G. A. & York, D. A. The MONA LISA hypothesis in the time of leptin. Recent Prog. Horm. Res. 53, 95–117 (1998).
Friedman, J. M. & Halaas, J. L. Leptin and the regulation of body weight in mammals. Nature 395, 763–770 (1998).
Inui, A. Feeding and body-weight regulation by hypothalamic neuropeptides — mediation of the actions of leptin. Trends Neurosci. 22, 62–67 (1999).
Kalra, S. P. et al. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr. Rev. 20, 68–100 (1999).
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J. & Baskin, D. G. Central nervous system control of food intake. Nature 404, 661–671 (2000).A recent review that provides a summary of hypothalamic effector molecules and neuronal circuits that control food intake and are regulated by leptin and insulin.
Inui, A. Transgenic approach to the study of body weight regulation. Pharmacol. Rev. 52, 35–61 (2000).
Inui, A. Transgenic study of energy homeostasis equation: implications and confounding influences. FASEB J. 14, 2158–2170 (2000).
Kojima, M. et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656–660 (1999).Describes the isolation of ghrelin, an endogenous ligand of the growth hormone secretagogue (GHS) receptor, from stomach extracts.
Kojima, M., Hosoda, H., Matsuo, H. & Kangawa, K. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol. Metab. 12, 118–122 (2001).
Frohman, L. A. & Jansson, J. O. Growth hormone-releasing hormone. Endocr. Rev. 7, 223–253 (1986).
Frohman, L. A., Downs, T. R. & Chomczynski, P. Regulation of growth hormone secretion. Front. Neuroendocrinol. 13, 344–405 (1992).
Smith, R. G. et al. Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Recent Prog. Horm. Res. 51, 261–285 (1996).
Frohman, L. A. et al. Secretagogues and the somatotrope: signaling and proliferation. Recent Prog. Horm. Res. 55, 269–291 (2000).
Momany, F. A. et al. Design, synthesis, and biological activity of peptides which release growth hormone in vitro. Endocrinology 108, 31–39 (1981).
Bowers, C. Y. et al. Structure–activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro. Endocrinology 106, 663–667 (1980).
Bowers, C. Y., Momany, F. A., Reynolds, G. A. & Hong, A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 114, 1537–1545 (1984).Reports the development of potent GHSs, including growth-hormone-releasing peptide 6 (GHRP-6).
Bowers, C. Y., Sartor, A. A., Reynolds, D. G. & Badger, T. A. M. On the actions of the growth hormone-releasing hexapeptide, GHRP-6. Endocrinology 128, 2027–2035 (1991).
Korbonits, M. & Grossman, A. Growth hormone-releasing peptide and its analogues: novel stimuli to growth hormone release. Trends Endocrinol. Metab. 6, 43–49 (1995).
Smith, R. G. et al. Peptidomimetic regulation of growth hormone secretion. Endocr. Rev. 18, 621–645 (1997).This review summarizes the GHS–GHS receptor system, its control of GH secretion and other physiological functions, as well as its clinical implications.
Casanueva, F. F. & Dieguez, C. Growth hormone secretagogues: physiological role and clinical utility. Trends Endocrinol. Metab. 10, 30–38 (1999).
Guillemin, R. et al. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 218, 585–587 (1982).
Dieguez, C. & Casanueva, F. F. Ghrelin: a step forward in the understanding of somatotroph cell function and growth regulation. Eur. J. Endocrinol. 142, 413–417 (2000).
Patchett, A. A. et al. The design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc. Natl Acad. Sci. USA 92, 7001–7005 (1995).
Howard, A. D. et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273, 974–977 (1996).The first demonstration of a complementary DNA that encodes the GHS receptor by the use of an expression cloning technique.
Dean, D. C. et al. Development of a high specific activity sulfur-35-labeled sulfonamide radioligand that allowed the identification of a new growth hormone secretagogue receptor. J. Med. Chem. 39, 1767–1770 (1996).
Pong, S. S. et al. Identification of a new G-protein-linked receptor for growth hormone secretagogues. Mol. Endocrinol. 10, 57–61 (1996).
McKee, K. K. et al. Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors. Mol. Endocrinol. 11, 415–423 (1997).
Guan, X. M. et al. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res. Mol. Brain Res. 48, 23–29 (1997).
Chen, C., Wu, D. & Clarke, I. J. Signal transduction systems employed by synthetic GH-releasing peptides in somatotrophs. J. Endocrinol. 148, 381–386 (1996).
Wren, A. M. et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141, 4325–4328 (2000).
Takaya, K. et al. Ghrelin strongly stimulates growth hormone release in humans. J. Clin. Endocrinol. Metab. 85, 4908–4911 (2000).
Date, Y. et al. Central effects of a novel acylated peptide, ghrelin, on growth hormone release in rats. Biochem. Biophys. Res. Commun. 275, 477–480 (2000).
Seoane, L. M. Ghrelin elicites a marked stimulatory effect on GH secretion in freely-moving rats. Eur. J. Endocrinol. 143, R7–9 (2000).
Peino, R. et al. Ghrelin-induced growth hormone secretion in humans. Eur. J. Endocrinol. 143, R11–14 (2000).
Bednarek, M. A. et al. Structure–function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J. Med. Chem. 43, 4370–4376 (2000).
Rehfeld, J. F. The new biology of gastrointestinal hormones. Physiol. Rev. 78, 1087–1108 (1998).
Hosoda, H., Kojima, M., Matsuo, H. & Kangawa, K. Purification and characterization of rat des-Gln14-ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor. J. Biol. Chem. 275, 21995–22000 (2000).
Gualillo, O. et al. Ghrelin, a novel placental-derived hormone. Endocrinology 142, 788–794 (2001).
Tullin, S. et al. Adenosine is an agonist of the growth hormone secretagogue receptor. Endocrinology 141, 3397–3402 (2000).
Smith, R. G. et al. Adenosine: a partial agonist of the growth hormone secretagogue receptor. Biochem. Biophys. Res. Commun. 276, 1306–1313 (2000).
Tomasetto, C. et al. Identification and characterization of a novel gastric peptide hormone: the motilin-related peptide. Gastroenterology 119, 395–405 (2000).Identifies a novel cDNA from the stomach that encodes a protein named prepromotilin-related peptide (on the basis of its sequence similarity to prepromotilin).
Itoh, Z. Motilin and clinical application. Peptides 18, 593–608 (1997).
Peeters, T. L. Erythromycin and other macrolides as prokinetic agents. Gastroenterology 105, 1886–1899 (1993).
Asakawa, A. et al. Ghrelin is an appetite-stimulatory signal from stomach with structual resemblance to motilin. Gastroenterology 120, 337–345 (2001).Ghrelin is the first appetite-stimulatory signal to be isolated from the stomach, and is the motilin-related peptide described in reference 44.
Del Rincon, J. P., Thorner, M. O. & Gaylinn, B. D. Motilin-related peptide and ghrelin: lessons from molecular techniques, peptide chemistry, and receptor biology. Gastroenterology 120, 587–588 (2001).
Coulie, B. J. & Miller, L. J. Identification of motilin-related peptide. Gastroenterology 120, 588–589 (2001).
Feighner, S. D. et al. Receptor for motilin identified in the human gastrointestinal system. Science 284, 2184–2188 (1999).
Thielemans, L., Depoortere, I., Assche, G. V., Bender, E. & Peeters, T. L. Demonstration of a functional motilin receptor in TE671 cells from human cerebellum. Brain Res. 895, 119–128 (2001).
Samson, W. K., Lumpkin, M. D., Nilaver, G. & McCann, S. M. Motilin: a novel growth hormone releasing agent. Brain Res. Bull. 12, 57–62 (1984).
Date, Y. et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141, 4255–4261 (2000).
Hosoda, H., Kojima, M., Matsuo, H. & Kangawa, K. Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem. Biophys. Res. Commun. 279, 909–913 (2001).
Depoortere, I., De Clercq, P., Svoboda, M., Bare, L. & Peeters, T. L. Identification of motilin mRNA in the brain of man and rabbit. Conservation of polymorphism of the motilin gene across species. Peptides 10, 1497–1503 (1997).
Okada, K. et al. Intracerebroventricular administration of the growth hormone-releasing peptide KP-102 increases food intake in free-feeding rats. Endocrinology 137, 5155–5158 (1996).
Torsello, A. et al. Novel hexarelin analogs stimulate feeding in the rat through a mechanism not involving growth hormone release. Eur. J. Pharmacol. 360, 123–129 (1998).
Locke, W., Kirgis, H. D., Bowers, C. Y. & Abdoh, A. A. Intracerebroventricular growth-hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats. Life Sci. 56, 1347–1352 (1995).
Ghigo, E. et al. Endocrine and non-endocrine activities of growth hormone secretagogues in humans. Horm. Res. 51, 9–15 (1999).
Tschöp, M., Smiley, D. L. & Heiman, M. L. Ghrelin induces adiposity in rodents. Nature 407, 908–913 (2000).Indicates an involvement of ghrelin in the regulation of energy balance by showing that ghrelin causes weight gain by reducing fat use.
Nakazato, M. et al. A role for ghrelin in the central regulation of feeding. Nature 409, 194–198 (2001).Ghrelin is a physiological mediator of feeding and acts through neuropeptide Y and agouti-related protein in the hypothalamus.
Shintani, M. et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 50, 227–232 (2001).
Hewson, A. K. & Dickson, S. L. Systemic administration of ghrelin induces Fos and Egr-1 proteins in the hypothalamic arcuate nucleus of fasted and fed rats. J. Neuroendocrinol. 12, 1047–1049 (2000).
Hirosue, Y. et al. Cholecystokinin octapeptide analogues suppress food intake via central CCK-A receptors in mice. Am. J. Physiol. 265, R481–486 (1993).
Smith, G. P. & Gibbs, J. Satiating effect of cholecystokinin. Ann. NY Acad. Sci. 713, 236–241 (1994).
Moran, T. H. Cholecystokinin and satiety: current perspectives. Nutrition 16, 858–865 (2000).
Schwartz, G. J. The role of gastrointestinal vagal afferents in the control of food intake: current prospects. Nutrition 16, 866–873 (2000).
Yoshida-Yoneda, E., O-Lee, T. J., Wei, J. Y., Vigna, S. R. & Tache, Y. Peripheral bombesin induces gastric vagal afferent activation in rats. Am. J. Physiol. 271, R1584–1593 (1996).
Kurosawa, M., Uvnas, M. K., Miyasaka, K. & Lundeberg, T. Interleukin-1 increases activity of the gastric vagal afferent nerve partly via stimulation of type A CCK receptor in anesthetized rats. J. Auton. Nerv. Syst. 12, 72–78 (1997).
Wang, Y. H., Tache, Y., Sheibel, A. B., Go, V. L. & Wei, J. Y. Two types of leptin-responsive gastric vagal afferent terminals: an in vitro single-unit study in rats. Am. J. Physiol. 273, R833–837 (1997).
Masuda, Y. et al. Ghrelin stimulates gastric acid secretion and motility in rats. Biochem. Biophys. Res. Commun. 276, 905–908 (2000).
Morley, J. E. Neuropeptide regulation of appetite and weight. Endocr. Rev. 8, 256–287 (1987).
Zhang, Y. et al. Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425–432 (1994).
Baskin, D. G., Breininger, J. F. & Schwartz, M. W. Leptin receptor mRNA identifies a subpopulation of neuropeptide Y neurons activated by fasting in rat hypothalamus. Diabetes 48, 828–833 (1999).
Cheung, C. C., Clifton, D. K. & Steiner, R. A. Proopiomelanocortin neurons are direct targets for leptin in the hypothalamus. Endocrinology 138, 4489–4492 (1997).
Campfield, L. A., Smith, F. J., Guisez, Y., Devos, R. & Burn, P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 269, 546–549 (1995).
Schwartz, M. W., Figlewicz, D. P., Baskin, D. G., Woods, S. C. & Porte, D. Jr Insulin in the brain: a hormonal regulator of energy balance. Endocr. Rev. 13, 387–414 (1992).
Ahima, R. S. & Flier, J. S. Leptin. Annu. Rev. Physiol. 62, 413–437 (2000).
Sawchenko, P. E. Toward a new neurobiology of energy balance, appetite, and obesity: the anatomists weigh in. J. Comp. Neurol. 402, 435–441 (1998).
Elmquist, J. K., Elias, C. F. & Saper, C. B. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 22, 221–232 (1999).
Satoh, N. et al. The arcuate nucleus as a primary site of satiety effect of leptin in rats. Neurosci. Lett. 224, 149–152 (1997).
Tang-Christensen, M., Holst, J. J., Hartmann, B. & Vrang, N. The arcuate nucleus is pivotal in mediating the anorectic effects of centrally administered leptin. Neuroreport 10, 1183–1187 (1999).
Dawson, R., Pelleymounter, M. A., Millard, W. J., Liu, S. & Eppler, B. Attenuation of leptin-mediated effects by monosodium glutamate-induced arcuate nucleus damage. Am. J. Physiol. 273, E202–206 (1997).
Tartaglia, L. A. et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 83, 1263–1271 (1995).
Tartaglia, L. A. The leptin receptor. J. Biol. Chem. 272, 6093–6096 (1997).
Hahn, T. M., Breininger, J. F., Baskin, D. G. & Schwartz, M. W. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nature Neurosci. 1, 271–272 (1998).
Broberger, C., Johansen, J., Johansson, C., Schalling, M. & Hökfelt, T. The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proc. Natl Acad. Sci. USA 95, 15043–15048 (1998).
Elias, C. F. et al. Leptin activates hypothalamic CART neurons projecting to the spinal cord. Neuron 21, 1375–1385 (1998).
Ollmann, M. M. et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278, 135–138 (1997).
Shutter, J. R. et al. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev. 11, 593–602 (1997).
Fan, W., Boston, B. A., Kesterson, R. A., Hruby, V. J. & Cone, R. D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 385, 165–168 (1997).
Stephens, T. W. et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 377, 530–532 (1995).
Kristensen, P. et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393, 72–76 (1998).
Schwartz, M. W. et al. Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes 46, 2119–2123 (1997).
Thornton, J. E., Cheung, C. C., Clifton, D. K., & Steiner, R. A. Regulation of hypothalamic proopiomelanocortin mRNA by leptin in ob/ob mice. Endocrinology 138, 5063–5066 (1997).
Cowley, M. A. et al. Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat. Neuron 24, 155–163 (1999).
Kalra, S. P., Dube, M. G., Sahu, A., Phelps, C. P. & Kalra, P. S. Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc. Natl Acad. Sci. USA 88, 10931–10935 (1991).
Dickson, S. L., Leng, G. & Robinson, I. C. Systemic administration of growth hormone-releasing peptide activates hypothalamic arcuate neurons. Neuroscience 53, 303–306 (1993).
Kamegai, J., Hasegawa, O., Minami, S., Sugihara, H. & Wakabayashi, I. The growth hormone-releasing peptide KP-102 induces c-fos expression in the arcuate nucleus. Brain Res. Mol. Brain Res. 39, 153–159 (1996).
Willesen, M. G., Kristensen, P. & Romer, J. Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology 70, 306–316 (1999).
Kamegai, J. et al. Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression. Endocrinology 141, 4797–4800 (2000).
Torsello, A. et al. Differential orexigenic effects of hexarelin and its analogs in the rat hypothalamus: indication for multiple growth hormone secretagogue receptor subtypes. Neuroendocrinology 72, 327–332 (2000).
Inui, A. Neuropeptide Y feeding receptors: are multiple subtypes involved? Trends Pharmacol. Sci. 20, 43–46 (1999).
Herzog, H. Y4 receptor deletion improves fertility in ob/ob mice without affecting the obese phenotype. Proc. VIth Int. Neuropeptide Y Conf. 06 (2001).
Naveilhan, P. et al. Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nature Med. 5, 1188–1193 (1999).
Sainsbury, A., Couzens, M., Lui, M. & Herzog, H. Critical role of Y2 receptors in body weight regulation revealed by adult-induced arcuate-specific gene deletion. Proc. VIth Int. Neuropeptide Y Conf. 014 (2001).
Hagan, M. M. et al. Long-term orexigenic effects of AGRP-(83-132) involve mechanisms other than melanocortin receptor blockade. Am. J. Physiol. 279, R47–52 (2000).
Hagan, M. M., Rushing, P. A., Benoit, S. C., Woods, S. C. & Seeley, R. J. Opioid receptor involvement in the effect of AgRP- (83-132) on food intake and food selection. Am. J. Physiol. 280, R814–821 (2001).
Erickson, J. C., Clegg, K. E. & Palmiter, R. D. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 381, 415–421 (1996).
Kohno, D. & Yada, T. Ghrelin increases cytosolic Ca2+ in the hypothalamic arcuate nucleus neurons. Jpn. J. Physiol. 51 (in the press).
Cowley, M. A. et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 411, 480–484 (2001).
Toshinai, K. et al. Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem. Biophys. Res. Commun. 281, 1220–1225 (2001).
Bado, A. et al. The stomach is a source of leptin. Nature 394, 790–793 (1998).Reports the presence of leptin in the stomach; this hormone is probably involved in CCK-mediated effects, including satiety.
Barrachina, M. D., Martinez, V., Wang, L., Wei, J. Y. & Tache, Y. Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice. Proc. Natl Acad. Sci. USA 94, 10455–10460 (1997).
Matson, C. A. & Ritter, R. C. Long-term CCK–leptin synergy suggests a role for CCK in the regulation of body weight. Am. J. Physiol. 276, R1038–1045 (1999).
Tolle, V. et al. In vivo and in vitro effects of ghrelin/motilin-related peptide on growth hormone secretion in the rat. Neuroendocrinology 73, 54–61 (2001).
Minami, S., Kamegai, J., Sugihara, H., Suzuki, N. & Wakabayashi, I. Growth hormone inhibits its own secretion by acting on the hypothalamus through its receptors on neuropeptide Y neurons in the arcuate nucleus and somatostatin neurons in the periventricular nucleus. Endocr. J. 45, S19–26 (1998).
Bowers, C. Y. Unnatural growth hormone-releasing peptide begets natural ghrelin. J. Clin. Endocrinol. Metab. 86, 1464–1469 (2001).
Korbonits, M. et al. The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J. Clin. Endocrinol. Metab. 86, 881–887 (2001).
Chapman, I. M. et al. Stimulation of the growth hormone (GH)-insulin-like growth factor-I axis by daily oral administration of a GH secretagogue (MK-0677) in healthy elderly subjects. J. Clin. Endocrinol. Metab. 81, 4249–4257 (1996).
Ghigo, E. et al. Biologic activities of growth hormone secretagogues in humans. Endocrine 14, 87–93 (2001).
Dieguez, C. & Casanueva, F. F. Influence of metabolic substrates and obesity on growth hormone secretion. Trends Endocrinol. Metab. 6, 55–59 (1995).
Tschöp, M. et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 50, 707–709 (2001).
Levin, B. E. & Keesey, R. E. Defense of differing body weight set points in diet-induced obese and resistant rats. Am. J. Physiol. 274, R412–419 (1998).
Levin, B. E. Arcuate NPY neurons and energy homeostasis in diet-induced obese and resistant rats. Am. J. Physiol. 276, R382–387 (1999).
Kaga, T. et al. Modest overexpression of NPY in the brain leads to obesity after high sucrose feeding. Diabetes 50, 1206–1210 (2001).
Ziotopoulou, M., Mantzoros, C. S., Hileman, S. M. & Flier, J. S. Differental expression of hypothalamic neuropeptides in the early phase of diet-induced obesity in mice. Am. J. Physiol. 279, E838–845 (2000).
Flier, J. S. Clinical review 94: what's in a name? In search of leptin's physiologic role. J. Clin. Endocrinol. Metab. 83, 1407–1413 (1998).
Ahima, R. S. et al. Role of leptin in the neuroendocrine response to fasting. Nature 382, 250–252 (1996).
Bray, G. A. & York, D. A. Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. Physiol. Rev. 59, 719–790 (1979).
Schwartz, M. W., Dallman, M. F. & Woods, S. C. Hypothalamic response to starvation: implications for the study of wasting disorders. Am. J. Physiol. 269, R949–957 (1995).
Inui, A. Cancer anorexia–cachexia syndrome: are neuropeptides the key? Cancer Res. 59, 4493–4501 (1999).
Plata-Salaman, C. R. Central nervous system mechanisms contributing to the cachexia–anorexia syndrome. Nutrition 16, 1009–1012 (2000).
Inui, A. Cytokine and sickness behavior: implications from knockout animal models. Trends Immunol. (in the press).
Gayle, D., Ilyin, S. E. & Plata-Salaman, C. R. Central nervous system IL-1 beta system and neuropeptide Y mRNAs during IL-1 beta-induced anorexia in rats. Brain Res. Bull. 44, 311–317 (1997).
Welle, S. Growth hormone and insulin-like growth factor-I as anabolic agents. Curr. Opin. Clin. Nutr. Metab. Care 1, 257–262 (1998).
Van den Berghe, G. Novel insights into the neuroendocrinology of critical illness. Eur. J. Endocrinol. 143, 1–13 (2000).
Murphy, M. G. et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J. Clin. Endocrinol. Metab. 83, 320–325 (1998).
Van den Berghe, G. et al. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. J. Clin. Endocrinol. Metab. 83, 309–319 (1998).
Hansen, B. S. et al. Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur. J. Endocrinol. 141, 180–189 (1999).
Leibowitz, S. F. Brain peptides and obesity: pharmacologic treatment. Obes. Res. 3, 573S–589S (1995).
Levine, A. S. & Billington, C. J. Obesity: progress through genetic manipulation. Curr. Biol. 8, R251–252 (1998).
I sincerely thank M. Kasuga and S. Baba of Kobe University, and M. Nakazato of Miyazaki Medical College, for stimulating discussions. The work was supported by grants from the Japanese Ministry of Education, Science, Sports, and Culture.
Cells of the anterior pituitary that are responsible for the production of growth hormone or somatotropin. Somatotroph adenomas cause acromegaly.
- HYPOTHALAMIC–HYPOPHYSEAL PORTAL SYSTEM
A system of blood vessels (portal veins) that links the capillaries of the hypothalamus with those of the pituitary.
A 22-amino-acid peptide produced in the mucosa of the small intestine, which stimulates contractions of the stomach and the release of pepsin.
- OXYNTIC MUCOSA
The acid-secreting parietal cells of the gastric mucosa.
- ENTEROCHROMAFFIN CELLS
Endocrine cells in the gastric mucosa, which synthesize and secrete histamine in response to stimulation by the hormone gastrin.
- PEPTIDE YY
A protein found in the small intestine, which inhibits molecule secretion from the exocrine pancreas.
A molecule from the protochordate Ciona intestinalis that represents the oldest true member of the cholecystokinin/gastrin family.
A member of the cholecystokinin/gastrin family isolated from the frog Hyla caerulea. It stimulates the secretion of gastric acid in the small intestine of several amphibians.
- RESPIRATORY QUOTIENT
The ratio of the volume of CO2 released to the volume of O2 consumed by a body tissue or an organism. The oxidation of carbohydrate results in a respiratory quotient of 1.0, whereas the oxidation of fat results in a quotient of 0.7. So, an increase in the respiratory quotient is sometimes related to increased use of carbohydrate and reduced use of fat to meet specific energy requirements.
- AGOUTI-RELATED PEPTIDE
An antagonist of melanocortin receptors that has an important role in the control of food intake. Administration and overexpression of this peptide result in hyperphagia and weight gain.
Peptides associated with feeding behaviour that have also been associated with disturbances of sleep such as narcolepsy.
A strong releaser of gastrin and cholecystokinin, which is found in the gut and the brain. It also has a mitogenic action in several cell types.
- PANCREATIC POLYPEPTIDE
A molecule, first detected as an impurity present in insulin preparations, which is released after food intake and seems to act as a regulator of pancreatic and gastrointestinal functions.
A disease characterized by the gradual enlargement of the bones of hands, feet, head and chest, and thickening of the skin, lips and vocal chords. It is caused by increased sensitivity to or increased production of growth hormone.
A phase in the human lifespan during which the levels of growth hormone are reduced, resulting in the dehydration of cells and organs, and a reduction in their size and function. Somatopause usually begins in people in their mid-forties, but can start earlier.
A condition caused by chronic diseases such as cancer, which is characterized by wasting, emaciation, feebleness and inanition.
About this article
Cite this article
Inui, A. Ghrelin: An orexigenic and somatotrophic signal from the stomach. Nat Rev Neurosci 2, 551–560 (2001). https://doi.org/10.1038/35086018
This article is cited by
The association of appetite and hormones (leptin, ghrelin, and Insulin) with resting metabolic rate in overweight/ obese women: a case–control study
BMC Nutrition (2022)
The gut hormone Allatostatin C/Somatostatin regulates food intake and metabolic homeostasis under nutrient stress
Nature Communications (2022)
Prospective, randomized, cross-over pilot study of the effects of Rikkunshito, a Japanese traditional herbal medicine, on anorexia and plasma-acylated ghrelin levels in lung cancer patients undergoing cisplatin-based chemotherapy
Investigational New Drugs (2020)
Scientific Reports (2018)
Increased ghrelin signaling prolongs survival in mouse models of human aging through activation of sirtuin1
Molecular Psychiatry (2016)